CClinicalTrials.gg
RecruitingNCT07477613BCI4STROKE-ArmUpdated Jul 7, 2026

Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke

An interventional study of BCI in Stroke, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The clinical investigation will take place in three phases:

  • A pre-selection/selection phase to ensure that the patient (lesion, symptoms, ability of our tools to detect your movement intentions, etc.) is suitable for a six-month intensive rehabilitation program using Brain-Machine Interface.
  • A second phase, consisting of implementing the intensive rehabilitation program, first in the traditional manner, without the Brain-Machine Interface (2 to 5 weeks), then, after implantation, with the Brain-Machine Interface (6 months).
  • During the third phase, only follow-up visits will be scheduled to ensure the longevity of the implants and the maintenance of the motor progress achieved through rehabilitation.
Read the detailed description

The BCI4STROKE-Arm clinical trial aims to demonstrate the proof of concept of innovative neurorehabilitation protocols in stroke patients based on the use of neuroprostheses. The objective is to define and evaluate rehabilitation protocols in chronic patients 6 to 18 months after a disabling stroke, promoting neuroplasticity processes through the use of the WIMAGINE neuroprosthesis and brain signal decoding algorithms. This brain-machine interface (BCI) based on the WIMAGINE electrocorticographic (ECoG) measurement implant will be used to control hand rehabilitation devices (functional electrical stimulation, robotic orthosis, and video observation therapy device) as part of the REHABCI system. Patients will follow a six-month intensive rehabilitation program (between three and five days per week) based on the use of this REHABCI system.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 10 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University Hospital, Grenoble is the lead sponsor of 815 studies on the registry; 205 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female, 18-70 years-old included
  2. Hemispheric ischemic stroke (> 1.5 cm on 2 imaging slices): cortical and/or subcortical lesion
  3. No decompressive craniectomy procedure performed
  4. Single unilateral stroke occurred 6 months to 18 months ago
  5. Disabling motor deficit of upper limb
  6. Patient able to follow a rehabilitation program
  7. Written consent to participate in the study from the patient and his/her legal representative
  8. Person affiliated to the social security system or beneficiary of such a system
  9. Highly effective or at least acceptable birth control method for women of childbearing potential

Exclusion criteria

Exclusion Criteria:

  1. Contraindication for Magnetic Resonance Imaging (MRI), Computed Tomography (CT-scan), Positron Emission Tomography (PET-scan)
  2. Contraindication for Transcranial Magnetic Stimulation (TMS), Electroencephalography (EEG), Magnetoencephalography (MEG)
  3. Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …)
  4. Severe leukoaraiosis
  5. Previous stroke (symptomatic deficit)
  6. Pre-existing dementia or significant cognitive deficits (MoCA)
  7. Intolerance to electrical stimulation
  8. Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS)
  9. Lesions on the scalp area, skin infections or dermatitis
  10. Epileptiform focus, even without clinical repercussions
  11. A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial
  12. Presence of brain implants of metal clips and/or brain stimulators
  13. Severe dystonia/involuntary movements

Patients with any of the following criteria cannot be included in this investigation:

  1. Contraindication for MRI, CT-scan, PET-scan
  2. Contraindication for TMS, EEG, MEG
  3. Contraindication for general anesthesia and for the surgery (such as thrombocytopenia, …)
  4. Severe leukoaraiosis
  5. Previous stroke (symptomatic deficit)
  6. Pre-existing dementia or significant cognitive deficits (MoCA)
  7. Intolerance to electrical stimulation
  8. Major spasticity in the upper limb (4 or 5 in the scale of Modified Ashworth Scale - MAS)
  9. Lesions on the scalp area, skin infections or dermatitis
  10. Epileptiform focus, even without clinical repercussions
  11. A health status, any clinical condition (eg, short life expectancy, and coexisting disease) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial
  12. Presence of brain implants of metal clips and/or brain stimulators
  13. Severe dystonia/involuntary movements
  14. Persons referred to in Articles L1121-5 to L1121-7 of the French Public Health Code (CSP), corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, individuals undergoing psychiatric care under Articles L.3212-1 and L.3213-1 who are not covered by Article L.1121-8, individuals admitted to a healthcare or social institution for purposes other than research, and minors.

Moreover, patient will not be included for implantation (exclusion criteria), if he is not eligible for a BCI rehabilitation protocol, as determined by the clinical team after multimodal selection tests. As examples, it can be due to:

  1. No existing residual corticospinal tracts proven tractography and/or Motor Evoked Potential (MEP)
  2. Unability to control a BCI or unwillingness to follow a BCI rehabilitation program, assessed by MEG-BCI
  3. Unability to activate any residual motor regions during motor imagery assessed by EEG and functional MRI (fMRI)
  4. Shape of the skull in the implantation site not concordant with the WIMAGINE implant, assessed by anatomical MRI
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    REHABCI System

    WIMAGINE-based upper-limb neurorehabilitation therapy

    Device: BCI

Interventions

  • DeviceBCI

    WIMAGINE

06

What researchers measure

Primary outcomes

  1. Safety of a wireless ECoG-based BCI using WIMAGINE® system in stroke patients

    Serious adverse events associated with the chronic implantation of an extradural ECoG measuring implant

    Time frame: 2 years after surgery

Secondary outcomes

  1. Efficacy of the task-oriented rehabilitation program using brain- controlled devices to perform daily life movements

    Increase in motricity and functional movements of the patient, utilizing assessments such as the Fugl- Meyer Assessment for Upper Extremity (FMA-UE), the Action Research Arm Test (ARAT), the Box and Block Test (BBT) and Range of Motion (RoM)

    Time frame: 7 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Benabid AL, Costecalde T, Eliseyev A, Charvet G, Verney A, Karakas S, Foerster M, Lambert A, Moriniere B, Abroug N, Schaeffer MC, Moly A, Sauter-Starace F, Ratel D, Moro C, Torres-Martinez N, Langar L, Oddoux M, Polosan M, Pezzani S, Auboiroux V, Aksenova T, Mestais C, Chabardes S. An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration. Lancet Neurol. 2019 Dec;18(12):1112-1122. doi: 10.1016/S1474-4422(19)30321-7. Epub 2019 Oct 3. PubMed 31587955 ↗
  • Mestais CS, Charvet G, Sauter-Starace F, Foerster M, Ratel D, Benabid AL. WIMAGINE: wireless 64-channel ECoG recording implant for long term clinical applications. IEEE Trans Neural Syst Rehabil Eng. 2015 Jan;23(1):10-21. doi: 10.1109/TNSRE.2014.2333541. Epub 2014 Jun 30. PubMed 25014960 ↗
  • Eliseyev A, Mestais C, Charvet G, Sauter F, Abroug N, Arizumi N, Cokgungor S, Costecalde T, Foerster M, Korczowski L, Moriniere B, Porcherot J, Pradal J, Ratel D, Tarrin N, Torres-Martinez N, Verney A, Aksenova T, Benabid AL. CLINATEC(R) BCI platform based on the ECoG-recording implant WIMAGINE(R) and the innovative signal-processing: preclinical results. Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:1222-5. doi: 10.1109/EMBC.2014.6943817. PubMed 25570185 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477613
Lead sponsor
University Hospital, Grenoble
Collaborators
French Alternative Energies and Atomic Energy Commission (CEA), Grenoble
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 8, 2026
Primary completion
Apr 8, 2029 (estimated)
Completion
Apr 8, 2031 (estimated)
Last update
Jul 7, 2026

Study contacts

Olivier DETANTE, MD, PhD
Contact
ODetante@chu-grenoble.fr
04 76 76 57 89
Caroline SANDRE-BALLESTER, PhD
Contact
csandreballester@chu-grenoble.fr
0438782851

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion